Vaxart, Inc. (VXRT)
OTCMKTS
· Delayed Price · Currency is USD
0.540
+0.030 (5.88%)
Jun 26, 2026, 3:59 PM EST
Vaxart Employees
Vaxart had 65 employees as of December 31, 2025. The number of employees decreased by 40 or -38.10% compared to the previous year.
Employees
65
Change (1Y)
-40
Growth (1Y)
-38.10%
Revenue / Employee
$3,932,446
Profits / Employee
$570,723
Market Cap
130.18M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| Cell Source | 1 |
| Northwest Biotherapeutics | 105 |
| CytoDyn | 13 |
| Nuo Therapeutics | 10 |
| Vicapsys Life Sciences | 2 |
Vaxart News
- 3 days ago - Vaxart Publishes Presentation Urging Shareholders to Vote “FOR” ALL Six of the Company's Highly Qualified Director Nominees on the WHITE Proxy Card TODAY - GlobeNewsWire
- 3 days ago - Vaxart Proxy statement: Proxy filing - Filings
- 3 days ago - Vaxart Proxy statement: Proxy filing - Filings
- 3 days ago - Vaxart Proxy statement: Proxy filing - Filings
- 3 days ago - Vaxart Proxy statement: Proxy filing - Filings
- 4 days ago - Vaxart receives contract modification for oral vaccine trial funding - TheFly
- 4 days ago - Vaxart Announces Update to BARDA Funding Award to Reflect Current Scope of COVID-19 Oral Pill Vaccine Trial - GlobeNewsWire
- 13 days ago - Vaxart's Two Newest Independent Directors James Breitmeyer, M.D., Ph.D., and Kevin Finney Send Letter to Shareholders Ahead of 2026 Annual Meeting - GlobeNewsWire